MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

Blood

Volumn 100, Issue 3, 2002, Pages 974-981

  Tafuri, Agostino ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Gregorj, Chiara ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Petrucci, Maria T ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Ricciardi, Maria R ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Mancini, Marco ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Cimino, Giuseppe ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Mecucci, Cristina ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Tedeschi, Alessandra ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Fioritoni, Giuseppe ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Ferrara, Felicetto ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Di Raimondo, Francesco ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Gallo, Eugenio ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Liso, Vincenzo ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Fabbiano, Francesco ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Cascavilla, Nicola ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Pizzolo, Giovanni ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Camera, Andrea ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Pane, Fabrizio ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Lanza, Francesco ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Cilloni, Daniela ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Annino, Luciana ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Vitale, Antonella ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Vegna, Maria L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Vignetti, Marco ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Foà, Robin ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Mandelli, Franco ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d Ospedale Civile di Pescara   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

^f Ospedale Ferrarotto   (Italy)

^g MOLINETTE HOSPITAL   (Italy)

^h UNIVERSITY OF BARI   (Italy)

ⁱ VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^j CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^k UNIVERSITY OF VERONA   (Italy)

^l UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^m Sezione di Ematologia Dipartimento di Scienze Biomediche Arciospedale S Anna   (Italy)

ⁿ SAN LUIGI GONZAGA HOSPITAL   (Italy)

^o Ospedale Civile Umberto I   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CARCINOGENESIS; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 0036682489     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0371     Document Type: Article

References (50)

1. Mechanisms of drug resistance in hematological malignancies
2. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
3. Resistance to chemotherapy in acute leukemia
4. Multiple drug resistance human KB carcinoma cells independently selected for high-level resistance to colchicine, Adriamycin, or vinblastine show changes in expression of specific proteins
5. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia
6. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications
7. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia
8. Expression of the multidrug resistance P-glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: Absence of correlation with response to treatment
9. Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations
10. Multicentric evaluation of MDR phenotype in leukemia
11. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
12. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
13. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia
14. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
15. Non-P-glycoprotein drug export mechanisms of multidrug resistance
16. The drug resistance-related protein LRP in the human major vault protein
17. Adolescent and adult acute lymphoblastic leukemia prognostic features and outcome of therapy. A study of 293 patients
18. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
19. Results of the vincristine, doxorubicine and dexamethasone regimen in adults with standard- and high-risk acute lymphoblastic leukemia
20. A five-drug remission induction regimen with intensive consolidation for adult with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811
21. Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL0288 randomized study
22. The impact of age on outcome in lymphoblastic leukemia: MRC UKALL X and XA compared: A report from the MRC Paediatric and adult working parties
23. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and leukemia group B study 8364
24. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study
25. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia
26. Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia
27. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study
28. Multidrug resistance (MDR1) gene expression in adult acute leukemia: Correlation with treatment outcome and in vitro sensitivity
29. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia
30. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients
31. MDR1 gene expression and drug resistance of AML cells
32. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroup with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group Study
33. Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia
34. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin
35. The biology and treatment of acute lymphoblastic leukemia in adults
36. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype
37. Drug transport variant without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with daunorubicin
38. Genestein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumor cell
39. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: Analysis and examples
40. Regression models and life-tables
41. Nonparametric estimation from incomplete observations
42. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity
43. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance
44. Flow cytometric determination of the multidrug resistance phenotype in acute leukemia
45. Expression of P-glycoprotein in adult T-cell leukemia cells
46. Clinical significance of P-glycoprotein expression and function for response in induction chemotherapy, relapse rate and overall survival in acute leukemia
47. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia
48. Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia